Arterial stiffness: a positive signal for grape seed extract and vitamin B9, without proof of clinical benefit

Improving a vascular marker does not necessarily mean preventing a heart attack. A network meta-analysis pooling 48 randomized trials suggests that grape seed extract and vitamin B9 reduce an indicator of arterial stiffness in people with cardiovascular disease or hypertension. However, the available abstract does not support a recommendation for supplementation.

Illustration of an artery and pulse wave propagation, an indicator used to assess arterial stiffness.
SupplementsEditorial illustration, not study data.

A comparison of 31 dietary interventions

The researchers pooled 48 randomized trials involving 2,719 participants and 31 interventions: supplements, nutraceuticals and dietary patterns. Their literature search covered trials published through January 2025.

This network meta-analysis aimed to compare the interventions on two vascular indicators: pulse wave velocity, or PWV, and augmentation index, or AIx. This type of analysis combines direct and indirect comparisons, but does not mean that every intervention was tested against all the others.

Two positive findings, but not across all indicators

Compared with placebo, grape seed extract and vitamin B9, or folic acid, appear to reduce pulse wave velocity. The authors rated the certainty of both findings as moderate. Since the units for the differences are not included in the supplied excerpt, their numerical magnitude is not reported here.

No intervention reached the threshold for statistical significance for augmentation index. Alpha-linolenic acid, dietary nitrates and wine extract showed the largest numerical improvements in this indicator, without establishing their effectiveness.

The reported sensitivity analyses were consistent with the main analysis. No publication bias was detected, which alone does not rule out the possibility of such bias.

An improved marker is not a cardiovascular event prevented

Arterial stiffness is a prognostic marker of vascular damage. But the reported findings concern intermediate measures, not a demonstrated reduction in heart attacks, strokes or mortality. Nor can they be applied directly to a healthy person.

The abstract does not detail doses, durations, formulations or adverse effects. It therefore provides no basis for choosing a commercial product or proposing a protocol. The authors themselves call for trials tailored to specific populations and doses before therapeutic recommendations can be established.

Limitations to keep in mind

Only the PubMed abstract was consulted. Detailed trial characteristics, heterogeneity, doses, durations and safety cannot be verified from the source material. Funding and conflicts of interest were not checked.

What we can take away

This review supports a research avenue for two supplements in patients with cardiovascular disease or hypertension, not a recommendation to buy them or proof that they prevent cardiovascular events.

Sources and provenance

Partager cet article

X f in

An error or a source to report? Contact the editorial team.